Forest lercanidipine

NDA for use of calcium channel blocker in hypertension will be submitted mid-2001, Forest says after acquiring rights to product from Recordati. A U.S. trial of more than 500 patients at 34 sites was recently completed. Launch is anticipated for mid-2002. Lercanidipine is currently marketed in Europe under the name Zanipid